Compare Citius Pharmaceuticals Inc (CTXR) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Teradyne, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Teradyne, Inc. trades at $406.9 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 4577.1× Citius Pharmaceuticals Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Teradyne, Inc. for 37 Days on average.
| CTXR | TER | |
|---|---|---|
Market Cap | $13.62M | $62.34B |
Volume | 132,438 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $1.82 | $483.84 |
52-Week Low | $0.48 | $132.05 |
Typical Hold Time | 16 Days | 37 Days |
Enterprise Value | $3.79M | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with 59.24% gross margins and consistent earnings beats, including Q2 2026 EPS of $2.47 versus $2.09 expected. Recent product launches like Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand.
TER offers compelling growth potential with 61% analyst buy ratings and a $461.50 price target representing 12% upside. However, elevated valuations (P/E 56.56) and cyclical semiconductor exposure present risks. The stock's outlook remains positive driven by AI infrastructure spending and expanding test portfolio, though investors should monitor competitive pressures and industry demand cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
